GlassScriptPhysician profile
Michael M Shroder
NPI 1770572794
$1,526.75
in general payments reported to CMS, 2019-2025
26 companies · $76.92 in 2025
The $76.92 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $34.55 · 2021: $35.09 · 2022: $340 · 2023: $284 · 2024: $211 · 2025: $76.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $188.79 | 2019-2025 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Ascend Therapeutics US, LLC | $187.74 | 2019-2023 | |
| Pfizer INC. | $148.29 | 2022-2024 | |
| Abbvie INC. | $141.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.27 | 2019-2023 | |
| Therapeuticsmd, INC. | $89.24 | 2019-2022 | |
| Coopersurgical, INC. | $71.96 | 2019-2023 | Paragard T 380a |
| Millicent US INC | $54.15 | 2020-2024 | Femring, Intrarosa |
| Mayne Pharma Commercial LLC | $51.95 | 2023 | |
| Mylan Pharmaceuticals INC. | $51.19 | 2022 | |
| Exeltis, USA INC. | $49.32 | 2021-2022 | |
| Astellas Pharma US INC | $48.84 | 2024 | Veozah |
| Organon LLC | $34.72 | 2023 | Nexplanon |
| Intuitive Surgical, INC. | $34.28 | 2024 | |
| Vertical Pharmaceuticals, LLC | $33.69 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32.29 | 2024 | Tisseel |
| Amag Pharmaceuticals, INC. | $28.49 | 2019 | |
| Covidien LP | $23.20 | 2019 | |
| Merck Sharp & Dohme LLC | $22.63 | 2023 | Gardasil 9 |
| Minerva Surgical, INC | $21.89 | 2022 | |
| Abbott Laboratories | $18.87 | 2019 | |
| Sumitomo Pharma America, INC. | $18.67 | 2023 | Myfembree |
| Duchesnay USA Incorporated | $18.42 | 2019 | |
| Lupin INC. | $17.31 | 2019 | |
| Myovant Sciences INC. | $17.21 | 2022 | |
| Avion Pharmaceuticals | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shroder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.